Introduction
The definition of success following radical prostatectomy has expanded from focusing on oncological cure to include both continence and potency. 1 To succeed in all three areas, we can use preoperative knowledge of disease stage when determining a surgical approach. Encountering organ-confined disease may lead a surgeon to focus on nerve-sparing techniques and thus better preserve both continence and potency. The problem with trying to predict preoperatively nonorgan-confined disease is that if the information is not accurate, this can mislead a surgeon and may result in poorer outcomes. 2 Over the years transrectal ultrasound has been used to evaluate extracapsular extension with relatively poor results. 3 With the growing popularity of magnetic resonance imaging (MRI), many research groups have tried to predict extracapsular extension with varying success along with increased expense. 4, 5 Brown et al.
2 explored the effect of preoperative endorectal MRI staging on positive surgical margin rates after radical prostatectomy in a cohort of 62 patients with a mean age of 58. They found a strong trend that patients undergraded on endorectal MRI had a much higher rate of positive surgical margins.
2 Imaging modalities have not been able to reliably predict disease stage, therefore a contemporary predictive model is needed.
The aim of our study was to construct an updated and reliable predictive model for determining non-organconfined disease. PSA screening has led to diagnosing prostate cancer in less advanced states. 6, 7 To account for the epidemiological changes seen in prostate cancer over the past 20 years, our model was generated from patients who underwent radical prostatectomy after 2000. Our goal was to predict the likelihood of non-organ-confined disease preoperatively to aid in determining a treatment modality or surgical approach.
Patients and methods
Information about a cohort of 1895 patients who underwent radical prostatectomy from 2000 to 2008 was retrieved from the Duke Prostate Center database. The modern PSA era was defined as having had a radical prostatectomy after 1 January 2000, as PSA screening practices at our institution reached uniformity and widespread use by this time period. The cohort consisted of both open and robotic approaches and, when indicated, a lymph node dissection was performed. Unilateral or bilateral nerve sparing was performed, if clinically indicated, based on preoperative erectile function and oncological parameters. Biopsy methods were at the discretion of the treating urologist. The biopsy and pathological specimens were reviewed by the attending pathologist for the respective case at our institution. Patients who did not have pathological tumor stage documented in the pathology report were excluded.
Race (African American, non-African American), body mass index (o25, 25-30 and 430), age at surgery, PSA level at diagnosis, biopsy Gleason sum (o7, 7 and 47), clinical tumor stage (cT1 and cT2/3), pathological Gleason sum (o7, 7 and 47) and seminal vesicle invasion underwent univariate analysis. Preoperative factors including race, body mass index, age at surgery, PSA biopsy Gleason sum and clinical tumor stage underwent binary logistical regression with regard to non-organ-confined disease. The Duke Interactive Clinical Equation for staging (DICE-S score) was created based on significant factors from logistic regression. The DICE-S score is a log odds equation that is able to combine the log odds ratios of all significant factors from the regression model into a single probability. The model was then internally validated using a bootstrapping technique. The DICE-S score allows a physician to preoperatively calculate the probability of encountering non-organ-confined disease by using readily available preoperative factors. Institutional review board approval was obtained before analysis.
Results
Clinicopathological characteristics of patients are summarized in Table 1 Predicting non-organ-confined prostate cancer AA Caire et al
The logistic regression model resulted in the log odds equation seen below.
A concordance index of 0.73 representing prediction accuracy was reached upon internal validation (Figure 1 ).
Discussion
This is the first study to the best of our knowledge that preoperatively predicts the likelihood of encountering non-organ-confined disease in the modern PSA era (X2000). PSA screening has been linked to earlier diagnosis, a greater proportion of organ-confined disease and improved survival outcomes when controlling for stage and grade. 6 Despite modern screening practices, PSA remains a predictor of disease stage. 8 Magheli et al. examined 13 434 men who underwent radical prostatectomy and found that when adjusting for clinical stage, age and race that both PSA and PSA density are predictive of extraprostatic extension. PSA was also found to be important in predicting non-organ-confined disease in our model and is included in the DICE-S score. Surgical therapy continues to offer excellent cancer control rates in organ-confined disease. 9 In a multiinstitutional study consisting of 9376 patients who underwent radical prostatectomy, Vickers et al. 9 concluded that organ-confined disease in the hands of an experienced surgeon had minimal recurrence rates. However, selecting patients for nerve-sparing prostatectomy is generally based on a preoperative assessment of the severity of disease. Organ-confined disease is always a candidate for a nerve-sparing procedure, whereas extracapsular extension may necessitate a wide local excision. 10 Having information about a patient's disease stage preoperatively is particularly beneficial in minimally invasive prostatectomies, as tactile feedback may be compromised in these procedures making it more difficult to assess extracapsular extension intraoperatively. 11 The ability of our study to preoperatively predict the likelihood of non-organ-confined disease may aid in choosing a treatment modality.
Clinical tumor stage is a well-known predictor of organ-confined disease. 12 Ohori et al. 12 examined 73 patients who were treated for clinically localized prostate cancer from 1989 to 2000 and showed clinical tumor stage to be predictive of extracapsular extension in all three nomograms. Partin et al 13 initially performed a multi-institutional study published in JAMA in 1997 that used PSA, clinical tumor stage and Gleason sums to predict pathological stage. Our study confirmed the importance of clinical tumor stage, PSA and Gleason sums in predicting non-organ-confined disease, however our updated model is more clinically useful as our cohort resembles the characteristics of modern day prostate cancer patients. In addition, our study incorporates patient age, which has also been associated with highrisk disease.
14 For example, men X70 have higher-stage disease and are more likely to be upstaged after radical prostatectomy.
14 Age is also included in models that predict biopsy Gleason sums, with older patients being associated with higher Gleason sums. 15 In our study, a biopsy Gleason sum of 47 was over three times as likely to encounter non-organ-confined disease compared with a biopsy Gleason sum of o7. Biopsy Gleason sums 47 have been reported to predict a significant likelihood of finding non-organ-confined disease. 16 In the aforementioned study, 85% of biopsies consisted of 12 or more cores and they were assessed using a modified Stanford protocol. 16 By using PSA and maximal percentage of tissue in a biopsy core, this group was able to differentiate disease stage in patients having a biopsy Gleason sum 47. 16 Nakanishi et al. 17 have also developed a model to predict those patients with Biopsy Gleason sums 47 who are at increased risk of having non-organ-confined disease. This group used specific biopsy features, such as maximum tumor length and basal core characteristics, to differentiate disease stage. 17 Although the above models are useful, our model was developed for more widespread use, as it used regularly available preoperative factors. Therefore, it will be more applicable in a referral situation, where biopsy information may be limited.
The DICE-S score has several limitations and is specific to the patient population seen at our medical center. Our institution is a high-volume tertiary referral academic Predicting non-organ-confined prostate cancer AA Caire et al center. Risk factors for non-organ-confined disease may differ based on patient populations. However, the concept and equation can be easily transferred and applied to different subsets of patients.
Conclusions
Using the DICE-S score-age, PSA, biopsy Gleason sum and clinical tumor stage predict non-organ-confined disease in radical prostatectomy. Preoperative disease stage information may aid in treatment decisions and surgical approach.
